首页 | 本学科首页   官方微博 | 高级检索  
     


Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study
Affiliation:1. Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;2. Department of Cardiovascular Medicine, Okayama City General Medical Center, Okayama, Japan;1. Section of Clinical Biochemistry, University of Verona, Verona, Italy;2. Emergency Department, University Hospital of Parma, Parma, Italy;3. Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Valencia, Spain;1. Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia;2. The University of Sydney, Sydney, NSW, Australia;1. Department of Cardiology, Austin Health, Melbourne, Vic, Australia;2. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Vic, Australia;3. Centre for Quality and Patient Safety Research, School of Nursing and Midwifery, Deakin University, Geelong, Vic, Australia;4. Faculty of Health, Arts and Design, Swinburne University of Technology, Melbourne, Vic, Australia;5. School of Health and Life Sciences, Federation University, Melbourne, Vic, Australia;1. Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan;2. Division of Cardiology, Department of Internal Medicine, Taipei City Hospital, Renai Branch, Taipei, Taiwan;3. Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan;4. Division of Cardiology, Department of Internal Medicine, Taipei Medical University, Taipei, Taiwan;5. Division of Cardiovascular Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan;6. Department of Information Management, Kai-Nan University, Taoyuan, Taiwan;7. Department of Industrial Engineering and Management, National Taipei University of Technology, Taipei, Taiwan;8. Department of Cardiology, Cathay General Hospital, Taipei, Taiwan;9. Department of Pharmacology, School of Medicine, Taipei Medical University, Taipei, Taiwan;1. Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia;2. University of Sydney, Sydney, NSW, Australia;3. Department of Vascular Surgery, Westmead Hospital, Sydney, NSW, Australia;1. Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia;2. Westmead Hospital, Western Sydney Local Health District, Sydney, NSW, Australia;3. The George Institute for Global Health, University of NSW, Sydney, NSW, Australia;4. Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, NSW, Australia;5. Sydney Health Partners, University of Sydney, NSW, Australia;6. Centre for Health Services Research and Cardiovascular Research Group, School of Population and Global Health, University of Western Australia, Perth, WA, Australia;7. Sydney Nursing School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia;8. National Heart Foundation of Australia, Australia
Abstract:
Keywords:Pulmonary hypertension  Sildenafil  Tadalafil  Soluble guanylate cyclase stimulator
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号